JT010

JT010 is a covalent and site-selective TRPA1 agonist. JT010 can be used in myocardial infarction research[1][2][3][4][5][6].

Product Specifications

CAS Number

[917562-33-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H318, H335

Target

TRP Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/JT010.html

Purity

99.48

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N(C1=NC(C2=CC=C(OC)C=C2)=CS1)CCCOC)CCl

Molecular Formula

C16H19ClN2O3S

Molecular Weight

354.85

Precautions

H302, H315, H318, H335

References & Citations

[1]Takaya J, et al. A Potent and Site-Selective Agonist of TRPA1. J Am Chem Soc. 2015 Dec 23;137 (50) :15859-64.|[2]Szabó K, et al. TRPA1 Covalent Ligand JT010 Modifies T Lymphocyte Activation. Biomolecules. 2024 May 28;14 (6) :632.|[3]Matsubara M, et al. Potent Activation of Human but Not Mouse TRPA1 by JT010. Int J Mol Sci. 2022 Nov 18;23 (22) :14297.|[4]Virk HS, et al. TGFβ1 induces resistance of human lung myofibroblasts to cell death via down-regulation of TRPA1 channels. Br J Pharmacol. 2021 Aug;178 (15) :2948-2962.|[5]Singh U, et al. Investigation of the Pathomechanism of Chronic Cough Using an In Vitro Approach. Clin Exp Allergy. 2025 Jan 21. |[6]Hoebart C, Kiss A, Pilz PM, Szabo PL, Podesser BK, Fischer MJM, Heber S. TRPA1 as Target in Myocardial Infarction. Int J Mol Sci. 2023 Jan 28;24 (3) :2516.